Coloplast IR presentation Q3 0607

Information about Coloplast IR presentation Q3 0607

Published on May 2, 2008

Author: Breezy

Source: authorstream.com

Content

Investor Presentation 9M 2006/07:  Investor Presentation 9M 2006/07 Coloplast in brief:  Coloplast in brief Coloplast’s products and services help patients achieve greater independence from medical challenges in 3 areas; ostomy care, urology & continence care and wound & skin care Global market leader in urology & continence care and European market leader in ostomy care Target of 15% annual growth in value creation measured as economic profit Value creation to be realised through double-digit CAGR and continuous reduction of the cost base Aspiring for global market leadership within all business areas through organic growth and acquisitions Main risk is health care reforms in main markets leading to reduced reimbursement prices Milestones:  Milestones Statutory meeting of Dansk Coloplast A/S 1957 Acq. of Mentor’s Urology Division & Selling off Sterling + Moving of US HQ to Minneapolis 2006 Announcement of 2012 objectives 2005 Factory in Hungary begins operations 2002 Several acquisitions: Amoena, Sween, SSL, HSC, Sterling 1994 – 2001 ‘3000 in 2000’ 1989 Coloplast's share is admitted for listing on the Copenhagen Stock Exchange 1983 Divisionalisation begins 1982 The first subsidiaries 1978 Amoena & Brachytherapy divested 2007 Revenue development 1957-2006:  Revenue development 1957-2006 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99 01 03 05 Coloplast has global presence :  Coloplast has global presence Three key customers:  Three key customers The health care professional Doctors and nurses. Primary concerns are user quality of life, product functioning and handling The end customer The user. Primary concern is quality of life The payer Concern is primarily product pricing and health economics Prof. Daniel Raudrant Hôtel Dieu, Lyon External factors - demand outlook:  External factors - demand outlook Demographics Surgical and medical trends Reimbursement reforms Focus on overall treatment costs Group buying and tender bid process Emerging markets Distribution & Parallel import Health Care reforms + + + - - The demand for products and services will continue to grow in terms of volume, but pressure on prices and margins will continue Market growth within Coloplast’s business areas estimated at 4-6% Reimbursement:  Reimbursement In the UK, a new consultation process is expected in September 2007 Coloplast expects no changes to reimbursement of ostomy- and continence care products and services before 2008 The German organisation is being strengthened ahead of potential effects from the health care regulation adopted 1 April 2007. Coloplast is strengthening the key account function and changes the sales force structure Income statement 9M 2006/07:  Income statement 9M 2006/07 Balance sheet, cash flows and key ratios 9M 2006/07:  Balance sheet, cash flows and key ratios 9M 2006/07 Impacts from acquisitions and restructurings:  Impacts from acquisitions and restructurings Impacts on profitability in 9M 2006/07 Estimated full year financial impacts Revenue development - business areas:  Revenue development - business areas Other Wound & Skin care 16% Urology & Continence care 40% Ostomy care 38% 6% Revenue development - geography:  Revenue development - geography 80% Europe 14% The Americas 6% Rest of World 6% On track for 2012 strategy targets:  On track for 2012 strategy targets Lean organisation with focus on customers, innovation and time to market New commercial organisation completed Strong growth momentum Acquisitions and divestments Integration of urology business completed within 3-6 months Brachytherapy divested (Q3) Breast Care divested (Q2) Implementation of global manufacturing strategy Relocation of production lines to Hungary progress according to plan New factories in Hungary and China completed Underlying production costs increased by 23%, sales increased by 25% Expectations and long-term targets :  Expectations and long-term targets Sales growth of 22-23% in local currencies of which around 10%-points will be organic growth - UPGRADED EBITDA margin of 18-19% and EBIT margin of 12-13% Investments in tangible assets of DKK 600m Corporate tax rate of 26% - CHANGED Net costs of integration and restructuring of around DKK 360m At least a doubling of economic profit (EP) every five years, based on the 2004/05 figures Organic growth of Coloplast’s revenue to at least DKK 14 billion Operating margin (EBIT) to exceed 18% Ostomy care:  Ostomy care For people who have lost their normal bowel- or bladder function due to cancer (80%) or inflammatory bowel diseases Main competitors are ConvaTec and Hollister Inc. Ambition to become global market leader and to reach two-digit market share in the US within 2-4 years Ostomy care :  Ostomy care SenSura is launched in 17 countries and sales continue to exceed estimates 12% organic growth in Q3 driven by satisfactory growth in US and main European markets HSC is strengthening market position through deployment of the ‘Managed Care’ strategy Urology & Continence care - customer segmentation:  Urology & Continence care - customer segmentation Location Customer Pathology DAY SURGERY BPH SUI Stones Urology surgeons Primarily Endourology REGIONAL CENTRES Highly specialised urologists Erectile Dysfunction (volume) Prostate Cancer OPERATING ROOM BPH SUI Erectile Dysfunction Prostate Cancer Urological surgeons Primarily open surgery OUTPATIENT CLINIC Nurses and Urologists SCI, MS, SB, BPH (diagnose and follow-up) WARD BPH (recovery) Pre- & post-op Care Nurses and urologists Good access to key decision-makers within a broad range of pathologies Broad product and service offerings, e.g. single-use products, urological tools, implants Urology & Continence care - market positioning:  Urology & Continence care - market positioning % of global market Global market leader in continence consumables with 20-25% market share Among global market leaders in urological specialties with 10% market share Strong position in the US market established with the acquisition of urology business European market leadership reinforced with 30% market share Tyco Hollister Braun Rüsch AstraTech Ethicon Boston Scientific AMS C.R. Bard Coloplast 15% Urology & Continence care :  Integration process to be completed within 3-6 months. Relocation in the US completed Acquired urology business shows organic growth on par with market growth Sales growth driven by intermittent catheters and urine bags Urology & Continence care Urology & Continence care - the product portfolio:  Urology & Continence care - the product portfolio Continence Consumables Urological Specialties Continence consumables Urological Urology & Continence Care Wound care ~ € 8 billion global market:  € 1.5 billion Wound care ~ € 8 billion global market Moist wound healing (MWH) Dry wound healing Chronic Acute € 1.0 billion € 1.0 billion € 1.5 billion Wound type Drugs and bio products VAC € 0.2 billion € 1.0 billion € 0.5 billion € 0.5 billion Product technology € 1.5 billion segment, growth 6-7% Wound & Skin care :  Sales growth driven by Biatain foam dressings The concept of Biatain - Ibu well received by customers, but sales performance still below estimates New strategy under implementation, which is expected to deliver double-digit growth within 1-2 years Wound & Skin care 22% ConvaTec 17% Other 3M 16% Urgo 7% J&J 8% S&N 12% Mölnlycke 10% Coloplast 8% Market share MWH - EU and US Global Operations strategy:  Global Operations strategy 2012 4300 employees 20% DK, 45% HU, 25% CN, 10% US/FR 10% annual volume growth 2006 3000 employees 50% DK, 20% HU, 5% CN, 25% US/FR 10% annual volume growth Achieve world-class manufacturing within the next three years Globally managed organisation with common standards for all factories and key processes 5% annual reduction in total unit cost from 2008 Global Operations strategy:  Production facilities in Denmark will be consolidated from six to three sites New factories located in Zhuhai, China and Nyirbator, Hungary Machine building in China Global Operations strategy - 500 1.000 1.500 2.000 2.500 3.000 3.500 4.000 Sep-06 Sep-07 Sep-08 Sep-09 Sep-10 Sep-11 Sep-12 Danish sites International sites Number of employees in production 2006-2012 Global Operations, status 9M 2007:  Global Operations, status 9M 2007 Zhuhai, China Construction completed and organisation under establishment First machine built in Zhuhai is operational in Tatabanya Nyirbator, Hungary Construction nearly completed First machines are transferred to rented facilities Employees are being trained in Tatabanya In Denmark, training has been intensified and shop floors are being transformed into offices Forward-looking statements:  Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast’s current expectations, estimates and assumptions and based on the information available to Coloplast at this time. Heavy fluctuations in the exchange rates of important currencies, significant changes in the healthcare sector or major changes in the world economy may impact Coloplast's possibilities of achieving the long-term objectives set as well as for fulfilling expectations and may affect the company’s financial outcomes.

Related presentations


Other presentations created by Breezy

Plant Anatomy
03. 01. 2008
0 views

Plant Anatomy

Learning Long Division
15. 06. 2007
0 views

Learning Long Division

ADO Net
24. 10. 2007
0 views

ADO Net

Ch 2 Chemistry of Life
05. 01. 2008
0 views

Ch 2 Chemistry of Life

REORGANIZATION
27. 09. 2007
0 views

REORGANIZATION

Enhanced Fujita Scale 6 23 04
05. 10. 2007
0 views

Enhanced Fujita Scale 6 23 04

severe convection punkka
07. 10. 2007
0 views

severe convection punkka

lsad07 psp
09. 10. 2007
0 views

lsad07 psp

idioms1
10. 10. 2007
0 views

idioms1

SabadosCiencia2006
13. 10. 2007
0 views

SabadosCiencia2006

Rousset EID06
19. 10. 2007
0 views

Rousset EID06

TheodoreRoosevelt
22. 10. 2007
0 views

TheodoreRoosevelt

Timss
17. 10. 2007
0 views

Timss

Wynn ASA 2000
04. 10. 2007
0 views

Wynn ASA 2000

aas strom
29. 08. 2007
0 views

aas strom

element connections
29. 08. 2007
0 views

element connections

hwr clustering
29. 08. 2007
0 views

hwr clustering

Pov map 20060717 1
29. 11. 2007
0 views

Pov map 20060717 1

CONSTRUCTING BUD VASES ADN BOWS
11. 12. 2007
0 views

CONSTRUCTING BUD VASES ADN BOWS

nobel talk
15. 10. 2007
0 views

nobel talk

18 FOSIS
24. 10. 2007
0 views

18 FOSIS

Lec 08 FO1 06 Urbanisation
01. 11. 2007
0 views

Lec 08 FO1 06 Urbanisation

America vs The World
22. 10. 2007
0 views

America vs The World

Vasco Da Gama Slide Show
07. 11. 2007
0 views

Vasco Da Gama Slide Show

Fliess
15. 11. 2007
0 views

Fliess

01 threat
19. 11. 2007
0 views

01 threat

Konsolen
21. 11. 2007
0 views

Konsolen

the dancers
23. 11. 2007
0 views

the dancers

Probil
26. 11. 2007
0 views

Probil

UNE Benz
27. 11. 2007
0 views

UNE Benz

Galaxies
29. 08. 2007
0 views

Galaxies

DB2 XML DatabaseFINAL
23. 10. 2007
0 views

DB2 XML DatabaseFINAL

akzonobel
15. 10. 2007
0 views

akzonobel

ilana
29. 08. 2007
0 views

ilana

lauter
07. 11. 2007
0 views

lauter

GradSch GPOs
04. 10. 2007
0 views

GradSch GPOs

PHYS402 01
16. 10. 2007
0 views

PHYS402 01

cry beloved
02. 08. 2007
0 views

cry beloved

curtis
02. 08. 2007
0 views

curtis

Chaplet of Divine Mercy
02. 08. 2007
0 views

Chaplet of Divine Mercy

CS583 opinion mining
02. 08. 2007
0 views

CS583 opinion mining

A TIME FOR ANDREW Pres 2
02. 08. 2007
0 views

A TIME FOR ANDREW Pres 2

arthur powerpoint 11 20 03
02. 08. 2007
0 views

arthur powerpoint 11 20 03

cheryl toner ific
02. 08. 2007
0 views

cheryl toner ific

bats
02. 08. 2007
0 views

bats

23 stavros thurs
02. 08. 2007
0 views

23 stavros thurs

aas04 jeff
29. 08. 2007
0 views

aas04 jeff

moustakis
29. 08. 2007
0 views

moustakis

irsurveys07
29. 08. 2007
0 views

irsurveys07

venice oct03
29. 08. 2007
0 views

venice oct03

Office of Homeleand Security
29. 10. 2007
0 views

Office of Homeleand Security

agn presentation 102106
29. 08. 2007
0 views

agn presentation 102106

ReginaSchulteLadbeck 042104
29. 08. 2007
0 views

ReginaSchulteLadbeck 042104

Weingarten
03. 01. 2008
0 views

Weingarten

Presentation NASDAQ
24. 02. 2008
0 views

Presentation NASDAQ

nov retail ebony
24. 02. 2008
0 views

nov retail ebony

APAsymp04AIDMAN
02. 08. 2007
0 views

APAsymp04AIDMAN

Ray Flores Roadmap
04. 03. 2008
0 views

Ray Flores Roadmap

Beloved
02. 08. 2007
0 views

Beloved

2004 4050S1 11 Levin
02. 08. 2007
0 views

2004 4050S1 11 Levin

Konstantinidis
29. 09. 2007
0 views

Konstantinidis

Qin and Han Dynasties
25. 03. 2008
0 views

Qin and Han Dynasties

andy powell presentation
02. 08. 2007
0 views

andy powell presentation

arena rome minier
13. 11. 2007
0 views

arena rome minier

Presentation010605
10. 04. 2008
0 views

Presentation010605

03edclark lecture
13. 04. 2008
0 views

03edclark lecture

richard mushotzky
29. 08. 2007
0 views

richard mushotzky

Lawrence D Boston 2006
14. 04. 2008
0 views

Lawrence D Boston 2006

DMCH13
16. 04. 2008
0 views

DMCH13

ERates
17. 04. 2008
0 views

ERates

JHAN 14
18. 04. 2008
0 views

JHAN 14

4884061 firstfileFILE
22. 04. 2008
0 views

4884061 firstfileFILE

ppt26
23. 12. 2007
0 views

ppt26

Operations
28. 04. 2008
0 views

Operations

CH10 Outline
07. 04. 2008
0 views

CH10 Outline

CIM research
30. 04. 2008
0 views

CIM research

komossa
29. 08. 2007
0 views

komossa

ieee sp 2004
18. 06. 2007
0 views

ieee sp 2004

icws 2006 3
18. 06. 2007
0 views

icws 2006 3

ICTP intro
18. 06. 2007
0 views

ICTP intro

human mating beh 2005
18. 06. 2007
0 views

human mating beh 2005

IMDS CIESP
14. 11. 2007
0 views

IMDS CIESP

welch adv camp july05
02. 10. 2007
0 views

welch adv camp july05

Glycosylation
15. 06. 2007
0 views

Glycosylation

Making a Story Board
15. 06. 2007
0 views

Making a Story Board

Story Literary Elements
15. 06. 2007
0 views

Story Literary Elements

Life Cycle of Plants and Animals
15. 06. 2007
0 views

Life Cycle of Plants and Animals

Session1Alila
02. 11. 2007
0 views

Session1Alila

beetleborers
02. 01. 2008
0 views

beetleborers

2006 IADB
10. 10. 2007
0 views

2006 IADB

robo wk1
03. 01. 2008
0 views

robo wk1

Rosemary Panama
22. 10. 2007
0 views

Rosemary Panama

ec06nicapan
25. 10. 2007
0 views

ec06nicapan

Allies Pre Training Module
02. 08. 2007
0 views

Allies Pre Training Module

Carmona
30. 12. 2007
0 views

Carmona

TheSuccessofSingapor e2006
27. 03. 2008
0 views

TheSuccessofSingapor e2006

Advisory Board Presentation
02. 08. 2007
0 views

Advisory Board Presentation

Cameron SAS44 A Century of OA
27. 02. 2008
0 views

Cameron SAS44 A Century of OA

dubrovnik
16. 10. 2007
0 views

dubrovnik

sprfett
07. 01. 2008
0 views

sprfett

mccune albright syndrome
15. 10. 2007
0 views

mccune albright syndrome

michael soendermann 2007
18. 10. 2007
0 views

michael soendermann 2007

astro12Summer12
29. 08. 2007
0 views

astro12Summer12

familyweek1
19. 02. 2008
0 views

familyweek1